Clear Search

Showing 1 result for “Carter K”.

August 2023

Upadacitinib en pacientes con artritis psoriásica y respuesta inadecuada a biológicos: resultados a 3 años de la extensión abierta del estudio de fase 3 controlado y aleatorizado SELECT-PsA 2

Clin Exp Rheumatol. 2023 doi: 10.55563/clinexprheumatol/8l7bbk. Epub ahead of print

Data from this open-label extension showed the efficacy of upadacitinib observed at 56 weeks was maintained through to 152 weeks in the treatment of patients with PsA. No cumulative adverse effects were observed, and no new safety signals were identified.